Literature DB >> 33529734

Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software.

Hanna J Kulbeth1, Saki Fukuda2, Lisa K Brents3.   

Abstract

Chronic prenatal exposure to opioids often causes fetal opioid dependence that leads to neonatal opioid withdrawal syndrome (NOWS) shortly after delivery. Rat models of NOWS often require quantifying neonatal withdrawal behaviors using time-consuming, labor-intensive manual scoring methods. The goal of this study was to automate quantification of opioid withdrawal in neonatal rat pups. Accordingly, we used the animal behavior software Ethovision® XT to analyze archived videos of rat pups subjected to precipitated opioid withdrawal testing on postnatal day 0. We compared results obtained from Ethovision® XT with those previously obtained from manual scoring. Two endpoints reported by Ethovision® XT, Distance Moved (cm) and Movement Duration (s), had strong positive linear relationships with manually derived global withdrawal scores (GWS; R2 > 0.73). Sensitivity and specificity of each endpoint to discriminate presence and absence of low-grade withdrawal were assessed by receiver operator characteristic curve analysis, which indicated that Distance Moved and Movement Duration had excellent accuracy (AUC > 0.90). Finally, we analyzed main and interaction effects of prenatal treatment (with vehicle or mu opioid receptor full agonists) and postnatal challenge (with saline or an opioid receptor antagonist) on each endpoint and determined they were similar for the manual and automated methods. These results show that Ethovision® XT software can reliably quantify opioid withdrawal in neonatal rat pups with non-inferiority to manual scoring even in videos that were not originally purposed and optimized for Ethovision® XT analysis. This faster and less labor-intensive method of analysis is expected to accelerate progress in preclinical studies of NOWS.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Locomotor activity; Neonatal opioid withdrawal syndrome (NOWS); Noldus Ethovision® XT; Rat model

Mesh:

Substances:

Year:  2021        PMID: 33529734      PMCID: PMC7965335          DOI: 10.1016/j.ntt.2021.106959

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  20 in total

1.  Gestational buprenorphine exposure: Effects on pregnancy, development, neonatal opioid withdrawal syndrome, and behavior in a translational rodent model.

Authors:  Chela M Wallin; Scott E Bowen; Chelsea L Roberge; Lauren M Richardson; Susanne Brummelte
Journal:  Drug Alcohol Depend       Date:  2019-10-17       Impact factor: 4.492

2.  Co-administration of dextromethorphan during pregnancy and throughout lactation significantly decreases the adverse effects associated with chronic morphine administration in rat offspring.

Authors:  P L Tao; G C Yeh; C H Su; Y H Wu
Journal:  Life Sci       Date:  2001-10-05       Impact factor: 5.037

3.  Symptoms of neonatal ethanol withdrawal.

Authors:  L B Robe; D S Gromisch; S Iosub
Journal:  Curr Alcohol       Date:  1981

4.  Opiate withdrawal in the neonatal rat: relationship to duration of treatment and naloxone dose.

Authors:  P Ceger; C M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2000-06       Impact factor: 4.530

5.  Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists.

Authors:  H Zhu; G A Barr
Journal:  Psychopharmacology (Berl)       Date:  2000-06       Impact factor: 4.530

6.  Opiate withdrawal in the fetal rat: a behavioral profile.

Authors:  K L Jones; G A Barr
Journal:  Pharmacol Biochem Behav       Date:  2000-06       Impact factor: 3.533

7.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

Authors:  Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis
Journal:  JAMA       Date:  2012-04-30       Impact factor: 56.272

Review 8.  The opioid-exposed newborn: assessment and pharmacologic management.

Authors:  Lauren M Jansson; Martha Velez; Cheryl Harrow
Journal:  J Opioid Manag       Date:  2009 Jan-Feb

9.  Role of noradrenergic hyperactivity in neonatal opiate abstinence.

Authors:  P J Little; R R Price; R K Hinton; C M Kuhn
Journal:  Drug Alcohol Depend       Date:  1996-05       Impact factor: 4.492

10.  Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012.

Authors:  S W Patrick; M M Davis; C U Lehmann; C U Lehman; W O Cooper
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.